The U.S. Food and Drug Administration (FDA) issued a complete response letter requesting additional information from AstraZeneca regarding the Biologics License Application (BLA) for subcutaneous (SC) ...

Congress has taken the final steps in the FY 2026 budget process, passing legislation that increases funding for lupus programs, including $27 million - the most in history - for lupus programs at the ...

Black History Month serves as a reminder to actively amplify Black voices, share stories and raise awareness throughout the year. This month, we’re featuring Danielle Storr, a Black lupus warrior who ...

We were joined experts who shared expert insights, practical tips, and personal experiences to empower patients to build ...

The U.S. Food and Drug Administration (FDA) has granted Biogen’s investigational drug, litifilimab, Breakthrough Therapy Designation for the treatment of cutaneous lupus erythematosus (CLE).

Our most recent episode of The Expert Series podcast explores the newly released SLE treatment guidelines and how they might affect patient care.

The Lupus Foundation of America has partnered with Carebox, the leading software platform for clinical trial patient recruitment, to launch the Lupus Clinical Trial Finder, a free platform available ...

In this episode of the Lupus Foundation of America's The Expert Series podcast, we focus on the newly released American College of Rheumatology treatment guidelines for systemic lupus erythematosus ...

The U.S. Food and Drug Administration (FDA) approved Gazyva® to treat adults with lupus nephritis in October 2025. Gazyva targets and removes harmful B cells to help protect the kidneys in people with ...

The U.S. House of Representatives has voted to increase funding for lupus programs across the federal government, a huge victory for the lupus community and lupus advocates nationwide. Congress ...